

#### ARANESP (darbepoetin alfa)

### **Pre - PA Allowance**

None

## **Prior-Approval Requirements**

#### Diagnoses

Patient must have **ONE** of the following:

- 1. Anemia associated with chronic renal failure
  - a. Serum ferritin ≥ 100 ng/ml (labs must have been taken within the last 3 months)

**AND ONE** of the following:

#### 1. If patient is NOT on dialysis

- a. Initial treatment: Hemoglobin < 10 g/dl\*
- b. Continuing treatment: Hemoglobin ≤ 10 g/dl\*

#### 2. If patient is ON dialysis

- a. Initial treatment: Hemoglobin < 10 g/dl\*
- b. Continuing treatment: Hemoglobin ≤ 11 g/dl\*

\* if the hemoglobin level exceeds this level then the prescribing physician must confirm that the dose will be held or reduced until the hemoglobin level returns to the required level.

- 2. Anemia secondary to chemotherapy
  - a. Concomitant myelosuppressive therapy and the anticipated outcome of therapy is NOT cure of cancer
  - b. There is a minimum of two additional months of planned chemotherapy
  - c. Must discontinue use of agent upon completion of the chemotherapy
  - d. Patient's anemia cannot be managed by transfusions
- 3. Myelodysplastic syndrome (MDS)
- 4. Anemia associated with Hepatitis C (HCV) treatment

#### **AND** the following

a. **NOT** used in combination with another erythropoiesis stimulating agent



ARANESP (darbepoetin alfa)

## **Prior - Approval Limits**

Duration 6 months

# Prior – Approval Renewal Requirements

Same as above

## Prior – Approval Renewal Limits

Same as above